This research presents an interdisciplinary exploration of the ethical, economic, and policy challenges shaping the future of genomics and regenerative medicine. Focusing on transformative technologies such as CRISPR gene editing and synthetic embryo models, the study critically examines key bioethical dilemmas, including non-therapeutic genetic enhancement, the moral status of lab-generated embryos, and the global inconsistencies in stem cell governance.A central contribution of this work is the introduction of the Genomic Equity Accessibility Formula (GEAF), a novel mathematical framework designed to quantitatively evaluate and improve equitable access to personalized genomic therapies. By integrating variables such as treatment cost, accessibility, ethical compliance, inequality, policy strength, and research efficiency, GEAF provides a scalable tool for policymakers, researchers, and global health stakeholders to model and optimize equity-driven interventions.Through scenario-based simulations grounded in real-world economic estimates, the study demonstrates that targeted strategie, such as tiered pricing, public-private partnerships, blockchain-enabled data sharing, and AI-driven research optimization can reduce therapy costs by up to 70% for underserved populations while significantly improving access.The paper further proposes the Equitable Genomics Initiative (EGI), a global policy framework combining ethical governance mechanisms (e.g., Ethical Enhancement Councils, Tiered Moral Frameworks, and International Stem Cell Accords) with technological and financial innovations to ensure inclusive and responsible scientific progress.By bridging bioethics, health economics, and computational modeling, this work offers a forward-looking blueprint for aligning genomic innovation with global health equity, emphasizing that the benefits of regenerative medicine must be accessible to all, not just privileged populations.
Peter Oloche David (Thu,) studied this question.